{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:52:29Z","timestamp":1793839949106,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Spero Therapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40505-7","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:19:57Z","timestamp":1771625997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Randomized study of the efficacy, safety, and pharmacokinetics of SPR720 for the treatment of Mycobacterium avium complex pulmonary disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Xilla T.","family":"Ussery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Critchley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekman L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John C.","family":"Pottage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Melnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal A.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"40505_CR1","volume-title":"Lung Nontuberculous Mycobacterial Infections","author":"A Bethencourt Mirabal","year":"2024","unstructured":"Bethencourt Mirabal, A., Nguyen, A. D. & Ferrer, G. Lung Nontuberculous Mycobacterial Infections (StatPearls Publishing, 2024)."},{"key":"40505_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/17476348.2023.2283135","volume":"17","author":"KA Hamed","year":"2023","unstructured":"Hamed, K. A. & Tillotson, G. A narrative review of nontuberculous mycobacterial pulmonary disease: Microbiology, epidemiology, diagnosis, and management challenges. Expert Rev. Respir. Med. 17, 973\u2013988. https:\/\/doi.org\/10.1080\/17476348.2023.2283135 (2023).","journal-title":"Expert Rev. Respir. Med."},{"key":"40505_CR3","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1186\/s12879-024-09965-y","volume":"24","author":"SJ Bents","year":"2024","unstructured":"Bents, S. J. et al. Nontuberculous mycobacterial pulmonary disease (NTM PD) incidence trends in the United States, 2010-2019. BMC Infect. Dis. 24, 1094. https:\/\/doi.org\/10.1186\/s12879-024-09965-y (2024).","journal-title":"BMC Infect. Dis."},{"key":"40505_CR4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1080\/13696998.2019.1620243","volume":"22","author":"TK Marras","year":"2019","unstructured":"Marras, T. K. et al. Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease. J. Med. Econ. 22, 1126\u20131133. https:\/\/doi.org\/10.1080\/13696998.2019.1620243 (2019).","journal-title":"J. Med. Econ."},{"key":"40505_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.rmed.2018.10.022","volume":"145","author":"TK Marras","year":"2018","unstructured":"Marras, T. K. et al. Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population. Respir. Med. 145, 80\u201388. https:\/\/doi.org\/10.1016\/j.rmed.2018.10.022 (2018).","journal-title":"Respir. Med."},{"key":"40505_CR6","doi-asserted-by":"publisher","first-page":"e91879","DOI":"10.1371\/journal.pone.0091879","volume":"9","author":"M Mirsaeidi","year":"2014","unstructured":"Mirsaeidi, M., Machado, R. F., Garcia, J. G. & Schraufnagel, D. E. Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: A population-based comparative study. PLoS ONE 9, e91879. https:\/\/doi.org\/10.1371\/journal.pone.0091879 (2014).","journal-title":"PLoS ONE"},{"key":"40505_CR7","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1093\/cid\/ciae421","volume":"79","author":"MH Nguyen","year":"2024","unstructured":"Nguyen, M. H. et al. Nontuberculous mycobacterial pulmonary disease: Patients, principles, and prospects. Clin. Infect. Dis. 79, e27\u2013e47. https:\/\/doi.org\/10.1093\/cid\/ciae421 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"40505_CR8","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.clinme.2024.100017","volume":"24","author":"K Kumar","year":"2024","unstructured":"Kumar, K. et al. Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management. Clin. Med. 24, 100017. https:\/\/doi.org\/10.1016\/j.clinme.2024.100017 (2024).","journal-title":"Clin. Med."},{"key":"40505_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.chest.2023.06.014","volume":"164","author":"MR Loebinger","year":"2023","unstructured":"Loebinger, M. R. et al. Risk factors for nontuberculous mycobacterial pulmonary disease: A systematic literature review and meta-analysis. Chest 164, 1115\u20131124. https:\/\/doi.org\/10.1016\/j.chest.2023.06.014 (2023).","journal-title":"Chest"},{"key":"40505_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12879-023-08468-6","volume":"23","author":"JE Marshall","year":"2023","unstructured":"Marshall, J. E., Mercaldo, R. A., Lipner, E. M. & Prevots, D. R. Incidence of nontuberculous mycobacteria infections among persons with cystic fibrosis in the United States (2010\u20132019) BMC Infect Dis. BMC Infect. Dis. 23, 489. https:\/\/doi.org\/10.1186\/s12879-023-08468-6 (2023).","journal-title":"BMC Infect. Dis."},{"key":"40505_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley, C. L. et al. Treatment of nontuberculous mycobacterial pulmonary disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline. Clin. Infect. Dis. 71, e1\u2013e36. https:\/\/doi.org\/10.1093\/cid\/ciaa241 (2020).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 2","key":"40505_CR12","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","volume":"72","author":"CS Haworth","year":"2017","unstructured":"Haworth, C. S. et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72(Suppl 2), ii1\u2013ii64. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210927 (2017).","journal-title":"Thorax"},{"key":"40505_CR13","doi-asserted-by":"publisher","first-page":"ofae128","DOI":"10.1093\/ofid\/ofae128","volume":"11","author":"C Cimino","year":"2024","unstructured":"Cimino, C. et al. Pharmacotherapeutic considerations in the treatment of nontuberculous mycobacterial infections: A primer for clinicians. Open Forum Infect. Dis. 11, ofae128. https:\/\/doi.org\/10.1093\/ofid\/ofae128 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"40505_CR14","doi-asserted-by":"publisher","first-page":"1468383","DOI":"10.3389\/fmicb.2024.1468383","volume":"15","author":"K Takeda","year":"2024","unstructured":"Takeda, K., Takazono, T. & Mukae, H. Drug-drug interactions in the management of non-tuberculous mycobacterial infections. Front. Microbiol. 15, 1468383. https:\/\/doi.org\/10.3389\/fmicb.2024.1468383 (2024).","journal-title":"Front. Microbiol."},{"key":"40505_CR15","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/14787210.2023.2270158","volume":"21","author":"KL Winthrop","year":"2023","unstructured":"Winthrop, K. L., Flume, P. & Hamed, K. A. Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720. Expert Rev. Anti Infect. Ther. 21, 1177\u20131187. https:\/\/doi.org\/10.1080\/14787210.2023.2270158 (2023).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"40505_CR16","volume-title":"Treatment of Mycobacterium avium subspecies hominissuis (MAH) Infection with a Novel Gyrase Inhibitor (SPR719\/SPR720) was associated with a Significant Decrease in Bacterial Load as assessed in Macrophages, Biofilm and in Mice, Poster SUN-540","author":"LE Bermudez","year":"2018","unstructured":"Bermudez, L. E., Palmer, A. & Rubio, A. Treatment of Mycobacterium avium subspecies hominissuis (MAH) Infection with a Novel Gyrase Inhibitor (SPR719\/SPR720) was associated with a Significant Decrease in Bacterial Load as assessed in Macrophages, Biofilm and in Mice, Poster SUN-540. (ASM Microbe\/American Society for Microbiology, 2018)."},{"key":"40505_CR17","doi-asserted-by":"publisher","first-page":"e01503","DOI":"10.1128\/AAC.01503-18","volume":"62","author":"BA Brown-Elliott","year":"2018","unstructured":"Brown-Elliott, B. A., Rubio, A. & Wallace, R. J. Jr. In vitro susceptibility testing of a novel benzimidazole, SPR719, against nontuberculous mycobacteria. Antimicrob. Agents Chemother. 62, e01503-e1518. https:\/\/doi.org\/10.1128\/AAC.01503-18 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40505_CR18","doi-asserted-by":"publisher","first-page":"e0009636","DOI":"10.1371\/journal.pntd.0009636","volume":"15","author":"SJ Pidot","year":"2021","unstructured":"Pidot, S. J., Porter, J. L., Lister, T. & Stinear, T. P. In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl. Trop. Dis. 15, e0009636. https:\/\/doi.org\/10.1371\/journal.pntd.0009636 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"40505_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jac\/dkae046","volume":"79","author":"N Cotroneo","year":"2024","unstructured":"Cotroneo, N. et al. Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection. J. Antimicrob. Chemother. 79, 875\u2013882. https:\/\/doi.org\/10.1093\/jac\/dkae046 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"40505_CR20","volume-title":"Potent Activity of a Novel Gyrase Inhibitor (SPR719\/SPR720) in vitro and in a Prolonged Acute Mycobacterium abscessus Mouse Model of Infection, Poster SUN-539","author":"A Rubio","year":"2018","unstructured":"Rubio, A., Stapleton, M. & Verma, D. Potent Activity of a Novel Gyrase Inhibitor (SPR719\/SPR720) in vitro and in a Prolonged Acute Mycobacterium abscessus Mouse Model of Infection, Poster SUN-539 (ASM Microbe\/ American Society for Microbiology, 2018)."},{"key":"40505_CR21","doi-asserted-by":"publisher","first-page":"S809","DOI":"10.1093\/ofid\/ofaa439.1817","volume":"7","author":"D Verma","year":"2020","unstructured":"Verma, D., Peterson, C., Cotroneo, N. S., Stokes, S. & Ordway, D. J. 1637. SPR720, a novel benzamidazole gyrase inhibitor, demonstrates potent efficacy against Mycobacterium avium ATCC 700898 in a chronic C3HeBFeJ mouse infection model. Open Forum Infect. Dis. 7, S809\u2013S809. https:\/\/doi.org\/10.1093\/ofid\/ofaa439.1817 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"40505_CR22","doi-asserted-by":"publisher","first-page":"S817","DOI":"10.1093\/ofid\/ofaa439.1837","volume":"7","author":"D Deshpande","year":"2020","unstructured":"Deshpande, D. et al. Pharmacokinetics\/pharmacodynamics of the novel gyrase inhibitor SPR719\/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium-complex disease. Open Forum Infect. Dis. 7, S817\u2013S817. https:\/\/doi.org\/10.1093\/ofid\/ofaa439.1837 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"40505_CR23","doi-asserted-by":"publisher","first-page":"e0110324","DOI":"10.1128\/aac.01103-24","volume":"68","author":"KA Rodvold","year":"2024","unstructured":"Rodvold, K. A., Gotfried, M. H., Ussery, X. T., Wong, S. L. & Hamad, K. A. Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers. Antimicrob. Agents Chemother. 68, e0110324. https:\/\/doi.org\/10.1128\/aac.01103-24 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40505_CR24","doi-asserted-by":"publisher","first-page":"e0120821","DOI":"10.1128\/AAC.01208-21","volume":"65","author":"AK Talley","year":"2021","unstructured":"Talley, A. K. et al. First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections. Antimicrob. Agents Chemother. 65, e0120821. https:\/\/doi.org\/10.1128\/AAC.01208-21 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40505_CR25","doi-asserted-by":"publisher","first-page":"106775","DOI":"10.1016\/j.ijantimicag.2023.106775","volume":"61","author":"SE Koele","year":"2023","unstructured":"Koele, S. E. et al. Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects. Int. J. Antimicrob. Agents 61, 106775. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106775 (2023).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"40505_CR26","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s42003-021-02184-0","volume":"4","author":"G Magombedze","year":"2021","unstructured":"Magombedze, G., Pasipanodya, J. G. & Gumbo, T. Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse. Commun. Biol. 4, 664. https:\/\/doi.org\/10.1038\/s42003-021-02184-0 (2021).","journal-title":"Commun. Biol."},{"key":"40505_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1515\/znc-2023-0146","volume":"79","author":"YA Al-Soud","year":"2024","unstructured":"Al-Soud, Y. A. et al. Novel 4-nitroimidazole analogues: Synthesis, in vitro biological evaluation, in silico studies, and molecular dynamics simulation. Zeitschrift Naturforschung 79, 61\u201371. https:\/\/doi.org\/10.1515\/znc-2023-0146 (2024).","journal-title":"Zeitschrift Naturforschung"},{"key":"40505_CR28","doi-asserted-by":"publisher","first-page":"e01321","DOI":"10.1128\/spectrum.01321-21","volume":"10","author":"WW Aragaw","year":"2022","unstructured":"Aragaw, W. W. et al. In vitro resistance against DNA gyrase inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiol. Spectr. 10, e01321-e1421. https:\/\/doi.org\/10.1128\/spectrum.01321-21 (2022).","journal-title":"Microbiol. Spectr."},{"key":"40505_CR29","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1128\/AAC.04347-14","volume":"59","author":"CP Locher","year":"2015","unstructured":"Locher, C. P. et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob. Agents Chemother. 59, 1455\u20131465. https:\/\/doi.org\/10.1128\/AAC.04347-14 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40505_CR30","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","volume":"198","author":"DE Griffith","year":"2018","unstructured":"Griffith, D. E. et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am. J. Respir. Crit. Care Med. 198, 1559\u20131569. https:\/\/doi.org\/10.1164\/rccm.201807-1318OC (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"40505_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","volume":"46","author":"CM Rubino","year":"2021","unstructured":"Rubino, C. M. et al. Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease. Eur. J. Drug Metab. Pharmacokinet. 46, 277\u2013287. https:\/\/doi.org\/10.1007\/s13318-020-00669-7 (2021).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"40505_CR32","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1164\/rccm.201501-0067OC","volume":"191","author":"DP Boyle","year":"2015","unstructured":"Boyle, D. P., Zembower, T. R., Reddy, S. & Qi, C. Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am. J. Respir. Crit. Care Med. 191, 1310\u20131317. https:\/\/doi.org\/10.1164\/rccm.201501-0067OC (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"40505_CR33","doi-asserted-by":"publisher","first-page":"e02469","DOI":"10.1128\/aac.02469-20","volume":"65","author":"LJ Pennings","year":"2021","unstructured":"Pennings, L. J., Ruth, M. M., Wertheim, H. F. L. & van Ingen, J. The benzimidazole SPR719 shows promising concentration dependent activity and synergy against nontuberculous mycobacteria. Antimicrob. Agents Chemother. 65, e02469-e2520. https:\/\/doi.org\/10.1128\/aac.02469-20 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40505_CR34","unstructured":"LiverTox: Clinical and research information on drug-induced liver injury [internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Mixed hepatitis. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547938\/. Accessed 13 February 2026."},{"key":"40505_CR35","doi-asserted-by":"publisher","first-page":"543","DOI":"10.14218\/JCTH.2021.00271","volume":"10","author":"LD Averbukh","year":"2022","unstructured":"Averbukh, L. D., Turshudzhyan, A., Wu, D. C. & Wu, G. Y. Statin-induced liver injury patterns: A clinical review. J. Clin. Transl. Hepatol. 10, 543\u2013552. https:\/\/doi.org\/10.14218\/JCTH.2021.00271 (2022).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"40505_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cgh.2014.07.054","volume":"13","author":"MA Martinez","year":"2015","unstructured":"Martinez, M. A. et al. Clinical and histologic features of azithromycin-induced liver injury. Clin. Gastroenterol. Hepatol. 13, 369-376.e3. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.054 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"40505_CR37","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith, D. E. et al. An official ATS\/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175, 367\u2013416. https:\/\/doi.org\/10.1164\/rccm.200604-571ST (2007).","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40505-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40505-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40505-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:17:37Z","timestamp":1774527457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40505-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40505"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40505-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"X.T.U., N.B., I.A.C., S.L.W., D.M., and K.A.H. are employees or former employees of Spero Therapeutics, Inc. J.C.P. Jr is a Board of Directors member of Spero Therapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10063"}}